Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Masiello

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|June 17, 2009
Bendamustine therapy in chronic lymphocytic leukemiaDavid Masiello, Anil Tulpule
Journal of Hematology & Oncology|November 14, 2009
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinibDavid Masiello, Gerry Gorospe, Allen S Yang
Journal of Hematology & Oncology|July 28, 2009
Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective studyJustin P Lee, Elliott Birnstein, David Masiello, et al.
The Journal of Biological Chemistry|May 17, 2002
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptorDavid Masiello, Shinta Cheng, Glenn J Bubley, et al.
Molecular Endocrinology (Baltimore, Md.)|July 17, 2004
Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cellsDavid Masiello, Shao-Yong Chen, Youyuan Xu, et al.
Cancer Biology & Therapy|January 16, 2007
Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancerDavid Masiello, M Golam Mohi, Nicole C McKnight, et al.
Molecular Endocrinology (Baltimore, Md.)|January 5, 2002
AR and ER interaction with a p21-activated kinase (PAK6)Suzanne R Lee, Sharon M Ramos, Andrew Ko, et al.
American Journal of Hematology|February 6, 2007
Hemoglobin SE disease: a concise reviewDavid Masiello, Matthew M Heeney, Adeboye H Adewoye, et al.
Current Cancer Drug Targets|December 17, 2010
The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cellsYong-Mi Kim, Hong Ma, Vivian G Oehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2004
Imatinib-induced regression of AIDS-related Kaposi's sarcomaHenry B Koon, Glenn J Bubley, Liron Pantanowitz, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|June 17, 2009
Bendamustine therapy in chronic lymphocytic leukemiaDavid Masiello, Anil Tulpule
Journal of Hematology & Oncology|November 14, 2009
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinibDavid Masiello, Gerry Gorospe, Allen S Yang
Journal of Hematology & Oncology|July 28, 2009
Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective studyJustin P Lee, Elliott Birnstein, David Masiello, et al.
The Journal of Biological Chemistry|May 17, 2002
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptorDavid Masiello, Shinta Cheng, Glenn J Bubley, et al.
Molecular Endocrinology (Baltimore, Md.)|July 17, 2004
Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cellsDavid Masiello, Shao-Yong Chen, Youyuan Xu, et al.
Cancer Biology & Therapy|January 16, 2007
Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancerDavid Masiello, M Golam Mohi, Nicole C McKnight, et al.
Molecular Endocrinology (Baltimore, Md.)|January 5, 2002
AR and ER interaction with a p21-activated kinase (PAK6)Suzanne R Lee, Sharon M Ramos, Andrew Ko, et al.
American Journal of Hematology|February 6, 2007
Hemoglobin SE disease: a concise reviewDavid Masiello, Matthew M Heeney, Adeboye H Adewoye, et al.
Current Cancer Drug Targets|December 17, 2010
The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cellsYong-Mi Kim, Hong Ma, Vivian G Oehler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2004
Imatinib-induced regression of AIDS-related Kaposi's sarcomaHenry B Koon, Glenn J Bubley, Liron Pantanowitz, et al.
Pageof 1